Browsing by Author "Kilickap, Saadettin"
Now showing items 1-12 of 12
-
Antibody responses to COVID-19 vaccination in cancer: a systematic review
Guven, Deniz Can; Sahin, Taha Koray; Kilickap, Saadettin; Uckun, Fatih M. (Frontiers Media SA, 2021)Introduction: After the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for ... -
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
Guven, Deniz Can; Acar, Ramazan; Yekedüz, Emre; Bilgetekin, İrem; Baytemur, Naziyet Kose; Erol, Cihan; Ceylan, Furkan Sacit; Kılıçkap, Saadettin (Mosby Inc., 2021)Background: Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that antibiotic (ATB) use either shortly before or after the ... -
The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme
Güven, Deniz Can; Aksun, Melek Seren; Çakır, İbrahim Yahya; Kılıçkap, Saadettin; Kertmen, Neyran (2021)Background: The association between obesity and sarcopenia (via temporal muscle thickness) with overall survival (OS) has been evaluated in several glioblastoma multiforme studies, however, the data are inconclusive. ... -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan; Yildirim, Hasan Cagri; Tunc, Sezai; Ozyurt, Neslihan; Ozdemir, Feyyaz; Sendur, Mehmet Ali Nahit; Kilickap, Saadettin (LIPPINCOTT WILLIAMS & WILKINS, 2022)Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ... -
Lower prognostic nutritional index is associated with poorer survival in patients receiving ımmune-checkpoint ınhibitors
Guven, Deniz C.; Aktepe, Oktay H.; Taban, Hakan; Aktas, Burak Y.; Guner, Gurkan; Yildirim, Hasan C.; Kilickap, Saadettin (Future Medicine, 2021)Aim: Blood-based biomarkers like prognostic nutritional index (PNI) are readily available biomarkers for immunotherapy efficacy, although the data are limited. So, we aimed to evaluate the association between PNI and overall ... -
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
Guven, Deniz Can; Sahin, Taha Koray; Yildirim, Hasan Cagri; Cesmeci, Engin; Gulbahce Incesu, Fatima Gul; Kilickap, Saadettin (BMJ, 2021)Background: We compared the new outpatient clinic referrals during the first 10 months of the COVID-19 pandemic with the year before. Methods: We compared baseline characteristics of the 2208 new referrals in 2020 (n=922) ... -
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Yekeduz, Emre; Erturk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Kilickap, Saadettin (Future Medicine, 2021)Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes ... -
Pazopanib-induced chylothorax in a patient with renal cell carcinoma
Koylu, Bahadir; Tekin, Fatih; Aktas, Burak Yasin; Kilickap, Saadettin; Koksal, Deniz (Wolters Kluwer, 2022)Pazopanib is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC). It is an anti-angiogenic agent, which blocks the activation signaling pathways of tyrosine kinases and prevents ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Tural, Deniz; Olmez, Omer Fatih; Sumbul, ahmet Taner; Ozhan, Nail; Cakar, Burcu; Paksoy Turkoz, Fatma; Kilickap, Saadettin (Springer, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Response to first‑line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
Tural, Deniz; Selcukbiricik, Fatih; Olmez, Omer Fatih; Sumbul, Ahmet Taner; Erman, Mustafa; Kilickap, Saadettin (Springer Link, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity in previous studies in patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of ATZ was modest. Therefore, finding ...
